## Highlights of This Issue 6367

### SPECIAL FEATURES

#### CCR Translations

6369 **Therapeutic Oligonucleotides: The Road Not Taken**
Cy A. Stein and Sanjay Goel

See commentary p. 6582

#### Molecular Pathways

6373 **The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression**
Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas

6381 **TLX1-Induced T-cell Acute Lymphoblastic Leukemia**
Kim De Keersmaecker and Adolfo A. Ferrando

#### CCR Focus

6388 **Antibody Conjugates: The Future Is Now**
Susan E. Bates

6389 **Antibody Conjugate Therapeutics: Challenges and Potential**
Bevery A. Teicher and Ravi V.J. Chari

6398 **Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox**
Robert J. Kreitman and Ira Pastan

6406 **Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends**
Martina Steiner and Dario Neri

6417 **Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin**
Alejandro D. Ricart

6428 **Brentuximab Vedotin (SGN-35)**
Jessica Katz, John E. Janik, and Anas Younes

### CANCER THERAPY: PRECLINICAL

6437 **Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer**
Patria M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish, and Mark X. Slawkowski

6448 **SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies**
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz, and John M. Lambert

6459 **Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC**
René H. Medema, Chia-Chi Lin, and James Chih-Hsin Yang

6467 **Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism**
Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Hu, and Bernard A. Fox

6482 **Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer**
Ning Jin, Tianyin Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball

6490 **The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization**
| 6500 | Significant Biological Role of Sp1 Transactivation in Multiple Myeloma | 6553 | Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma |
| 6510 | Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells | 6563 | PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients |
| 6522 | EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies | 6574 | Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin |
| 6531 | Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers | 6582 | A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer |

**CANCER THERAPY: CLINICAL**

- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
- Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials

**IMAGING, DIAGNOSIS, PROGNOSIS**

- High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma
- Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

- Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials
- PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

**Prediction of Single- versus Multi-Medication-Related Adverse Drug Events in Head and Neck Squamous Cell Carcinoma**

| 6592 | Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials | 6592 | Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials |

**The Journal of Clinical and Translational Research**

www.aacrjournals.org
LETTERS TO THE EDITOR

KRAS rs61764370 in Epithelial Ovarian Cancer – Letter
Joanne B. Weidhaas and Frank J. Slack

KRAS rs61764370 in Epithelial Ovarian Cancer – Response
Harvey A. Risch, Andrew Berchuck, and Paul D.P. Pharoah; for the Ovarian Cancer Association Consortium

ABOUT THE COVER

The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vargatef, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vargatef combination, even in patients with mutant KRAS. For details, see the article by Poindessous and colleagues on page 6522 of this issue.